Vaccination Response to an Ongoing Meningitis Outbreak: Uptake and Attitudes among Men Who Have Sex with Men in Los Angeles, CA

Ian Holloway, Department of Social Welfare, Los Angeles
Elizabeth Wu, University of California
Jennifer Gildner, University of California
Vincent Fenimore, University of California
Paula Frew, Emory University

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017, Pages S418-S418
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx163.1046
Permanent URL: https://pid.emory.edu/ark:/25593/s6gff

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.1046

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed January 20, 2018 4:49 AM EST
1350. Vaccination Response to an Ongoing Meningitis Outbreak: Uptake and Attitudes Among Men Who Have Sex with Men in Los Angeles, CA

Ian Holliday, PhD, MSW, MPH; Elizabeth Wu, MPH; Jennifer Galdner, MSPh; Vincent Fenimore, Ph.D, M.Ed. and Paula Frew, Ph.D, MA, MPH; 1Department of Social Welfare, 3250 Charles Young Drive, Los Angeles, California, 2Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, 3Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, Georgia

Session: 152. Herpes Zoster Vaccine
Friday, October 6, 2017: 12:30 PM

Background. Men who have sex with men (MSM) are at high risk for invasive meningococcal disease (IMD). Following a 2016 IMD outbreak in Southern California, public health officials issued an advisory that urge at-risk adult gay and bisexual men to consider meningococcal vaccination. However, widespread uptake of meningococcal vaccines among MSM remains unknown.

Methods. From November 2016 through February 2017, we used venue-based sampling to recruit MSM in Los Angeles (N = 513). Eligible participants completed a 30-minute iPad survey that included items on MCV4 status, sexual behavior, vaccination knowledge and behaviors among other factors. Chi-square and independent sample t-tests were used to determine bivariate associations. Statistically significant variables from bivariate analyses were included in a multivariate logistic regression model predicting MCV4 uptake.

Results. Participants were young (M=33, SD=10) and racially/ethnically diverse: White (35.7%), Black/African American (14.6%), Hispanic (36.5%), Asian/Pacific Islander (4.1%), Other (9.2%). Reported MCV4 immunization among MSM (25.4%) and MSM living with HIV (37.7%) was low. Statistically significant correlates of MCV4 uptake included: younger age (aOR=5.43), previously diagnosed STI (aOR=2.21), believing MCV4 vaccination was important (aOR=3.45), having confidence someone who had received the vaccination (aOR=3.21), and MSM's perceived health risk, vaccine confidence, and knowledge of someone who received the MCV4 vaccine were important indicators of meningitis immunization in this outbreak context. Provider and public health education efforts may be enhanced by messages that emphasize personal health risks, the safety and efficacy of MCV4, and the importance of meningococcal vaccines for men's health.

Popular opinion leader programs facilitated by someone who had been vaccinated are warranted to enhance MCV4 uptake.

Disclosures. All authors: No reported disclosures.

Poster Abstracts

S418 • OFID 2017:4 (Suppl 1)

1351. Bivalent Norovirus VLP Vaccine Candidate in Older Adults: Impact of MPL and a Second Dose in a Randomized, Controlled, Double-Blind Clinical Trial

Jim Sherwood, BA1; Jakob Cramer, MD1; Nancy Bouvère Le Cam, MD1; Stella Lin, PhD; Frank Baehner, MD1; Paul Mendelman, MD2 and Astrid Borkowski, MD1; 1Takeda Pharmaceuticals International AG, Zurich, Switzerland, 2Takeda Development Center Americas, Inc., Deerfield, Illinois

Session: 152. Herpes Zoster Vaccine
Friday, October 6, 2017: 12:30 PM

Background. Acute norovirus (NoV) gastroenteritis may cause significant morbidity in healthy adults and can prove fatal in older subjects. We investigated the safety and immunogenicity in older adults of one or two doses of an intramuscular bivalent virus-like particle (VLP) vaccine candidate (genotypes GI.1 and multivalent GI.4c) formulated with alum and with and without MPL (3-O-deacyl-4′-monophosphoryl lipid A) adjuvant.

Methods. In a phase II, double-blind, controlled trial, 294 healthy adults ≥ 60 years of age randomized to 4 equal groups received one or two immunizations 28 days apart. One dose groups received placebo (saline) on Day 1. Vaccine formulations contained 50μg Al(OH)3 adjuvant with 15μg GI.1 and 50μg GII.4c VLP antigens. The fifth group of 26 healthy 18–49 year-olds received one dose of MPL-free vaccine. Humoral immunity was assessed as ELISA pan-Ig and histo-blood group antigen blocking (HBGA) antibody titers at Days 1, 8, 29 and 57. Cell-mediated immunity (CMI) and antibody indices (AI) were also measured. Safety was assessed as solicited local and systemic adverse events (AE) for 7 days, and unsolicited AEs until Day 28 after each vaccination.

Results. Marked increases in pan-Ig and HBGA to both genotypes occurred by Day 28 after first vaccination. Geometric mean titers were similar in magnitude in all groups when compared with those to a single vaccine dose in 18–49 year-olds. No clinically relevant differences in CMI responses or changes in antibody avidity were observed between formulations. Both formulations were generally well tolerated, the most frequent reaction being mild pain at the injection site. No vaccine-related SAEs were reported.

Conclusion. Older adults aged 60 years and older displayed immune responses to NoV VLP vaccines that were similar to those in younger adults with no apparent signs of immunosenescence. These data support the further development of the MPL-free vaccine candidate in older adults.

Disclosures. All authors: No reported disclosures.